What Cancer Feeds On

This comprehensive review from Texas Tech University Health Sciences Center examines how cancer cells go far beyond the classic Warburg effect. The authors detail how aerobic glycolysis — fermenting glucose to lactate even with oxygen present — is just the entry point. Cancer cells reprogram an entire network of interlinked pathways: amino acid metabolism, one-carbon metabolism, the pentose phosphate pathway (for nucleotide synthesis), and antioxidant machinery. Crucially, the review focuses on the nutrient transporters — the molecular "intake valves" on cell membranes — that make all of this possible, spanning plasma membrane, mitochondrial, and lysosomal transporters. These transporters are identified as novel drug targets for next-generation cancer therapeutics.

Researchers at China Medical University's Fourth Affiliated Hospital provide a deep dive into cancer's "glutamine addiction." After metabolic reprogramming, tumor cells consume glutamine at vastly increased rates to generate the building blocks of life: amino acids, nucleotides, fatty acids, and more — all essential for unlimited proliferation. The paper maps out how glutamine is imported, metabolized, and transported, then explains how major oncogenes (C-MYC, KRAS, HIF, and p53) directly control glutamine metabolism. The review also surveys clinical anti-cancer agents that target glutamine pathways, including CB-839 (telaglenastat), and assesses their prospects.

From the University of Toyama (Japan), this review explores the critical and underappreciated link between cancer metabolism and immune evasion. Cancer cells don't just use metabolic fuels to grow — they weaponize metabolism to escape immune destruction. By accelerating glucose and amino acid consumption, tumors create a nutrient-depleted, acidic, lactate-flooded microenvironment that paralyzes T cells, NK cells, and macrophages. The authors focus on how the Warburg effect and glutamine addiction create an immunosuppressive "metabolic force field" around tumors, and propose that disrupting these metabolic pathways could directly enhance immunotherapy effectiveness.

Scientists at The Catholic University of Korea uncovered a previously unknown molecular mechanism driving glutamine addiction in liver cancer (HCC). The splicing factor SF3B4 — highly expressed in HCC — controls which version (isoform) of the key glutaminase enzyme GLS1 the cell produces. SF3B4 preferentially generates the GAC isoform of GLS1, which has significantly higher catalytic activity than the KGA isoform. This is a "metabolic tuning" mechanism: the cancer doesn't just increase glutaminase quantity, it switches to a more powerful enzyme variant. When SF3B4 is blocked, glutaminolysis drops, mitochondrial respiration on glutamine decreases, and tumor cells — especially when glucose is scarce — struggle to survive, revealing SF3B4 as a potential drug target.

Researchers from Tongji Hospital (Huazhong University of Science and Technology) and Beijing Children's Hospital synthesize the latest science on lactate — the metabolic "exhaust" of glycolysis — and its surprisingly active role in cancer biology. Far from being inert waste, lactate is now understood to be a key immunosuppressive agent, a recycled fuel (lactate shuttle), and an epigenetic regulator (via histone lactylation — a newly discovered modification where lactate chemically tags DNA-packaging proteins, changing which genes are expressed). The paper makes the case that monitoring and targeting lactate anabolism and lactate transport proteins (MCT1/MCT4) represents a promising and underexplored strategy for improving cancer immunotherapy outcomes.

From Shandong Cancer Hospital and Shandong University, this advanced review examines how the cytokine MIF (Macrophage Migration Inhibitory Factor) acts as a master coordinator linking inflammation to the full spectrum of tumor metabolism — glucose, lipids, and amino acids. MIF signals through CD74 and co-receptors (CXCR2/CXCR4/CXCR7), activating PI3K/AKT and ERK pathways to drive aerobic glycolysis. It also controls the SREBP and PPAR lipid regulatory systems to orchestrate de novo lipogenesis, fatty acid oxidation flexibility, and cholesterol/membrane homeostasis in tumor cells. Additionally, MIF reshapes amino acid transport, glutamine utilization, and redox balance. The paper rigorously grades evidence and proposes imaging- and flux-based approaches to translate MIF-axis findings into clinical trials.

Researchers from Iran University of Medical Sciences and Liaoning University identify ACSL3 (Acyl-CoA Synthetase Long Chain Family Member 3) as a key lipid metabolism enzyme strongly linked to poor prognosis in liver cancer (HCC). ACSL3 is consistently overexpressed in HCC models, and its high expression correlates with STAT3 signaling pathway activation — a powerful oncogenic signaling hub. Bioinformatic analyses revealed that high ACSL3 drives upregulation of key lipogenic enzymes, creating a self-amplifying feedback loop: cancer activates lipid synthesis, which sustains STAT3 signaling, which further activates lipid synthesis. The study also found a striking correlation between ACSL3 expression and PD-L1 — the primary immune checkpoint molecule — linking de novo lipogenesis directly to immune evasion.

A Beijing Friendship Hospital / Capital Medical University team reviews the bidirectional crosstalk between the tumor's physical scaffold (extracellular matrix, ECM) and cancer lipid metabolism. They reveal that these two systems form a self-amplifying feedback circuit: ECM remodeling (driven by tumor-associated proteases and structural proteins like collagen) regulates lipid anabolism and catabolism, which in turn provides the energy and membrane materials for further ECM degradation and tumor invasion. Reprogrammed lipid metabolism — de novo lipogenesis, fatty acid oxidation (FAO), and lipid peroxidation — is characterized as a metabolic hallmark of cancer. The authors identify critical intervention nodes in this circuit, including collagen-driven cues and intracellular FAO pathways, as targets to disrupt tumor-stroma co-evolution and improve drug efficacy.